secwatch / observer
8-K filed April 30, 2026, 7:59 PM ET ticker OSRH CIK 0001840425
other material confidence high sentiment positive materiality 0.85

OSR Holdings signs $815M VXM01 license with BCM Europe; largest shareholder pledges entire stake as collateral

OSR Holdings, Inc.

item 1.01item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-26-049967
form_type
8-K
ticker
OSRH
cik
0001840425
company_name
OSR Holdings, Inc.
filed_at
2026-04-30T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.088611+00:00
generated_at
2026-05-15T01:05:32.017386+00:00
sec_items
["1.01", "7.01", "9.01"]
event_type
other_material
sentiment
positive
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-26-049967
json_url
https://secwatch.observer/filing/0001213900-26-049967.json
markdown_url
https://secwatch.observer/filing/0001213900-26-049967.md
text_url
https://secwatch.observer/filing/0001213900-26-049967.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/0001213900-26-049967-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1840425/000121390026049967/ea0288465-8k_osrhold.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

90de46d6f5719e4999c930c75ce8e6e3e50c020d

OSR Holdings, Inc. entered into License Agreement with BCM Europe AG valued at up to $815,000,000 (effective 2026-04-29).

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

HOVR

New Horizon Aircraft raises ~$20M in registered direct offering of 9.25M shares at $2.15

New Horizon Aircraft Ltd. May 8, 2026, 7:59 PM ET other_material Items 1.01, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

On May 6, 2026, New Horizon Aircraft Ltd. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”) an aggregate of 9,254,889 our Class A ordinary shares, without par value (the “Shares", and each Class A ordinary share with no par value in the authorized share structure of the Company, a “Common Share”). The offering price per Share is $2.15, for aggregate gross proceeds to the Company from the Offering of approximately $19.9 million

Filing page SEC filing

AVTX

Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31

Avalo Therapeutics, Inc. May 7, 2026, 7:59 PM ET other_material Items 1.01, 2.02, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent

Filing page SEC filing

CLRB

Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock

Filing page SEC filing

XRN

Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP

Chiron Real Estate Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.

Filing page SEC filing

NKTR

Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO

NEKTAR THERAPEUTICS May 8, 2026, 7:59 PM ET other_material Items 1.01, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.

Filing page SEC filing

AREB

American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville

AMERICAN REBEL HOLDINGS INC May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Global Exclusive License Agreement On April 29, 2026, OSR Holdings, Inc. (the “Company”), together with its wholly-owned subsidiary Vaximm AG (“Vaximm”), entered into a Global Exclusive License Agreement (the “License

Comparable filing

Streeterville Series E Preferred Exchange Agreements On April 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-26-049967
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.